Analisis Kadar Interferon Gamma pada Penderita TB
Abstract
This study aims to determine the levels of IFN-γ in patients with SO TB and RO TB and to analyze the differences in IFN-γ levels in patients with RO TB and SO TB. The research method used is descriptive-analytical with a cross-sectional approach. The results showed that of the 50 respondents with Pulmonary TB, the largest percentage of respondents were male (52%) and in the adult age category (44%). The examination results showed that the average IFN-γ level in patients with RO TB was lower, namely 65.38 pg/ml compared to the average IFN-γ level in patients with SO TB, namely 82.37 pg/ml. In conclusion, there is a significant difference between IFN-γ levels in patients with SO TB and RO TB.
Keywords: Interferon Gamma, Drug-Resistant TB (RO TB)
References
Berns, S. A., Isakova, J. A., & Pekhtereva, P. I. (2022). Therapeutic Potential of Interferon-Gamma in Tuberculosis. ADMET & DMPK, 10(1), 63–73. https://doi.org/10.5599/admet.1078.
Chandra, P., Grigsby, S. J., & Philips, J. A. (2022). Immune Evasion and Provocation by Mycobacterium Tuberculosis. Nature Reviews. Microbiology, 20(12), 750–766. https://doi.org/10.1038/s41579-022-00763-4
Chowdhury, K., Ahmad, R., Sinha, S., Dutta, S., & Haque, M. (2023). Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now. Cureus, 15(2), e35154. https://doi.org/10.7759/cureus.35154
Cyntia, Suci, L., O., Olivianto, E., Tjahjono, H.A., Sulistijono, E. (2022). Peran Interferon Gamma Induced Protein-10 (IP-10) Dalam Diagnosis Tuberkulosis Aktif Pada Anak. Universitas Brawijaya. http://repository.ub.ac.id./id/print/187808
Dean, A. S., Tosas Auguet, O., Glaziou, P., Zignol, M., Ismail, N., Kasaeva, T., & Floyd, K. (2022). 25 Years of Surveillance of Drug-Resistant Tuberculosis: Achievements, Challenges, and Way Forward. The Lancet. Infectious Diseases, 22(7), e191–e196. https://doi.org/10.1016/S1473-3099(21)00808-2
Dinkes Provinsi Jambi. (2022). Profil Kesehatan Tahun 2022. https://dinkes.jambiprov.go.id/all_profil_kesehatan
Espinosa-Pereiro, J., Sánchez-Montalvá, A., Aznar, M. L., & Espiau, M. (2022). MDR Tuberculosis Treatment. Medicina (Kaunas, Lithuania), 58(2), 188. https://doi.org/10.3390/medicina58020188
Fukunaga, R., Glaziou, P., Harris, J. B., Date, A., Floyd, K., & Kasaeva, T. (2021). Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets - Worldwide, 2019. MMWR. Morbidity and Mortality Weekly Report, 70(12), 427–430. https://doi.org/10.15585/mmwr.mm7012a4
Jang, J. G., & Chung, J. H. (2020). Diagnosis and Treatment of Multidrug-Resistant Tuberculosis. Yeungnam University Journal of Medicine, 37(4), 277–285. https://doi.org/10.12701/yujm.2020.00626
Januarie, K. C., Uhuo, O. V., Iwuoha, E., & Feleni, U. (2022). Recent Advances in the Detection of Interferon-Gamma as a TB Biomarker. Analytical and Bioanalytical Chemistry, 414(2), 907–921. https://doi.org/10.1007/s00216-021-03702-z
Jones, R. M., Adams, K. N., Eldesouky, H. E., & Sherman, D. R. (2022). The Evolving Biology of Mycobacterium Tuberculosis Drug Resistance. Frontiers in Cellular and Infection Microbiology, 12, 1027394. https://doi.org/10.3389/fcimb.2022.1027394
Kemenkes, R. (2020). Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia. Dirjen Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan Republik Indonesia. https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://repository.kemkes.go.id/book/1283&ved=2ahUKEwjthoLLhfaJAxXXzDgGHeq8NsUQFnoECBUQAQ&usg=AOvVaw0zjbnBkI_pbOx5QfO3pDJT
Kemenkes., R. (2020). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. 1–139. Dirjen Pengembangan dan Pengendalian Penyakit. https://repository.kemkes.go.id/book/124
Kherabi, Y., Fréchet-Jachym, M., Rioux, C., Yazdanpanah, Y., Méchaï, F., Pourcher, V., Robert, J., Guglielmetti, L., & MDR-TB Management Group (2022). Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019. Emerging Infectious Diseases, 28(9), 1796–1804. https://doi.org/10.3201/eid2809.220458
Kuncara, R. B., Wikandari, R. J., Widiyanto, D., Sulistiasmi, W. (2024). Differences In Interferon Gamma Levels In Treatment Of Tuberculosis In Intensive Phase And Advanced Phase. Jurnal Biosains Pascasarjana, 26(1), 72–76. https://doi.org/10.20473/jbp.v26i1.2024.72-76
Ravesloot-Chávez, M. M., Van Dis, E., & Stanley, S. A. (2021). The Innate Immune Response to Mycobacterium Tuberculosis Infection. Annual Review of Immunology, 39, 611–637. https://doi.org/10.1146/annurev-immunol-093019-010426
Shah, I., Poojari, V., & Meshram, H. (2020). Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis. Indian Journal of Pediatrics, 87(10), 833–839. https://doi.org/10.1007/s12098-020-03230-1
Shanmuganathan, G., Orujyan, D., Narinyan, W., Poladian, N., Dhama, S., Parthasarathy, A., Ha, A., Tran, D., Velpuri, P., Nguyen, K. H., & Venketaraman, V. (2022). Role of Interferons in Mycobacterium Tuberculosis Infection. Clinics and Practice, 12(5), 788–796. https://doi.org/10.3390/clinpract12050082
Sterling, T. R., Njie, G., Zenner, D., Cohn, D. L., Reves, R., Ahmed, A., Menzies, D., Horsburgh, C. R., Jr, Crane, C. M., Burgos, M., LoBue, P., Winston, C. A., & Belknap, R. (2020). Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR. Recommendations and reports : Morbidity and Mortality Weekly Report. Recommendations and Reports, 69(1), 1–11. https://doi.org/10.15585/mmwr.rr6901a1
Tiberi, S., Utjesanovic, N., Galvin, J., Centis, R., D'Ambrosio, L., van den Boom, M., Zumla, A., & Migliori, G. B. (2022). Drug resistant TB - Latest Developments in Epidemiology, Diagnostics and Management. International Journal of Infectious Diseases : IJID : Official publication of the International Society for Infectious Diseases, 124 Suppl 1, S20–S25. https://doi.org/10.1016/j.ijid.2022.03.026
Trimulyani, A., Abror, Y.K., Marliana, N., Merdekawati, F. (2024). Analisis Kadar Interferon Gamma Menggunakan Metode Fluorescence Imunoassay (Fia) Dan Enzyme-Linked Immunosorbent Assay (Elisa) Pada Pasien Tuberkulosis. Jurnal Kesehatan Siliwangi, 4(3), 1006-1013. https://jurnal.polkesban.ac.id/index.php/jks/article/view/1992
WHO. (2022). Tuberculosis Consolidated Guidelines on Module 4: Treatment—Drug-Resistant Tuberculosis Treatment, 2022 Update; WHO Guidelines Approved by the Guidelines Review Committee. Geneva, Switzerland. URL: https://iris.who.int/handle/10665/365308
WHO. (2022). Global Tuberculosis Report. World Health Organization; 2022. Licence: cc BY-NC-sa 3.0 IGO. URL: https://iris.who.int/handle/10665/363752
Chandra, P., Grigsby, S. J., & Philips, J. A. (2022). Immune Evasion and Provocation by Mycobacterium Tuberculosis. Nature Reviews. Microbiology, 20(12), 750–766. https://doi.org/10.1038/s41579-022-00763-4
Chowdhury, K., Ahmad, R., Sinha, S., Dutta, S., & Haque, M. (2023). Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now. Cureus, 15(2), e35154. https://doi.org/10.7759/cureus.35154
Cyntia, Suci, L., O., Olivianto, E., Tjahjono, H.A., Sulistijono, E. (2022). Peran Interferon Gamma Induced Protein-10 (IP-10) Dalam Diagnosis Tuberkulosis Aktif Pada Anak. Universitas Brawijaya. http://repository.ub.ac.id./id/print/187808
Dean, A. S., Tosas Auguet, O., Glaziou, P., Zignol, M., Ismail, N., Kasaeva, T., & Floyd, K. (2022). 25 Years of Surveillance of Drug-Resistant Tuberculosis: Achievements, Challenges, and Way Forward. The Lancet. Infectious Diseases, 22(7), e191–e196. https://doi.org/10.1016/S1473-3099(21)00808-2
Dinkes Provinsi Jambi. (2022). Profil Kesehatan Tahun 2022. https://dinkes.jambiprov.go.id/all_profil_kesehatan
Espinosa-Pereiro, J., Sánchez-Montalvá, A., Aznar, M. L., & Espiau, M. (2022). MDR Tuberculosis Treatment. Medicina (Kaunas, Lithuania), 58(2), 188. https://doi.org/10.3390/medicina58020188
Fukunaga, R., Glaziou, P., Harris, J. B., Date, A., Floyd, K., & Kasaeva, T. (2021). Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets - Worldwide, 2019. MMWR. Morbidity and Mortality Weekly Report, 70(12), 427–430. https://doi.org/10.15585/mmwr.mm7012a4
Jang, J. G., & Chung, J. H. (2020). Diagnosis and Treatment of Multidrug-Resistant Tuberculosis. Yeungnam University Journal of Medicine, 37(4), 277–285. https://doi.org/10.12701/yujm.2020.00626
Januarie, K. C., Uhuo, O. V., Iwuoha, E., & Feleni, U. (2022). Recent Advances in the Detection of Interferon-Gamma as a TB Biomarker. Analytical and Bioanalytical Chemistry, 414(2), 907–921. https://doi.org/10.1007/s00216-021-03702-z
Jones, R. M., Adams, K. N., Eldesouky, H. E., & Sherman, D. R. (2022). The Evolving Biology of Mycobacterium Tuberculosis Drug Resistance. Frontiers in Cellular and Infection Microbiology, 12, 1027394. https://doi.org/10.3389/fcimb.2022.1027394
Kemenkes, R. (2020). Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia. Dirjen Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan Republik Indonesia. https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://repository.kemkes.go.id/book/1283&ved=2ahUKEwjthoLLhfaJAxXXzDgGHeq8NsUQFnoECBUQAQ&usg=AOvVaw0zjbnBkI_pbOx5QfO3pDJT
Kemenkes., R. (2020). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. 1–139. Dirjen Pengembangan dan Pengendalian Penyakit. https://repository.kemkes.go.id/book/124
Kherabi, Y., Fréchet-Jachym, M., Rioux, C., Yazdanpanah, Y., Méchaï, F., Pourcher, V., Robert, J., Guglielmetti, L., & MDR-TB Management Group (2022). Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019. Emerging Infectious Diseases, 28(9), 1796–1804. https://doi.org/10.3201/eid2809.220458
Kuncara, R. B., Wikandari, R. J., Widiyanto, D., Sulistiasmi, W. (2024). Differences In Interferon Gamma Levels In Treatment Of Tuberculosis In Intensive Phase And Advanced Phase. Jurnal Biosains Pascasarjana, 26(1), 72–76. https://doi.org/10.20473/jbp.v26i1.2024.72-76
Ravesloot-Chávez, M. M., Van Dis, E., & Stanley, S. A. (2021). The Innate Immune Response to Mycobacterium Tuberculosis Infection. Annual Review of Immunology, 39, 611–637. https://doi.org/10.1146/annurev-immunol-093019-010426
Shah, I., Poojari, V., & Meshram, H. (2020). Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis. Indian Journal of Pediatrics, 87(10), 833–839. https://doi.org/10.1007/s12098-020-03230-1
Shanmuganathan, G., Orujyan, D., Narinyan, W., Poladian, N., Dhama, S., Parthasarathy, A., Ha, A., Tran, D., Velpuri, P., Nguyen, K. H., & Venketaraman, V. (2022). Role of Interferons in Mycobacterium Tuberculosis Infection. Clinics and Practice, 12(5), 788–796. https://doi.org/10.3390/clinpract12050082
Sterling, T. R., Njie, G., Zenner, D., Cohn, D. L., Reves, R., Ahmed, A., Menzies, D., Horsburgh, C. R., Jr, Crane, C. M., Burgos, M., LoBue, P., Winston, C. A., & Belknap, R. (2020). Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR. Recommendations and reports : Morbidity and Mortality Weekly Report. Recommendations and Reports, 69(1), 1–11. https://doi.org/10.15585/mmwr.rr6901a1
Tiberi, S., Utjesanovic, N., Galvin, J., Centis, R., D'Ambrosio, L., van den Boom, M., Zumla, A., & Migliori, G. B. (2022). Drug resistant TB - Latest Developments in Epidemiology, Diagnostics and Management. International Journal of Infectious Diseases : IJID : Official publication of the International Society for Infectious Diseases, 124 Suppl 1, S20–S25. https://doi.org/10.1016/j.ijid.2022.03.026
Trimulyani, A., Abror, Y.K., Marliana, N., Merdekawati, F. (2024). Analisis Kadar Interferon Gamma Menggunakan Metode Fluorescence Imunoassay (Fia) Dan Enzyme-Linked Immunosorbent Assay (Elisa) Pada Pasien Tuberkulosis. Jurnal Kesehatan Siliwangi, 4(3), 1006-1013. https://jurnal.polkesban.ac.id/index.php/jks/article/view/1992
WHO. (2022). Tuberculosis Consolidated Guidelines on Module 4: Treatment—Drug-Resistant Tuberculosis Treatment, 2022 Update; WHO Guidelines Approved by the Guidelines Review Committee. Geneva, Switzerland. URL: https://iris.who.int/handle/10665/365308
WHO. (2022). Global Tuberculosis Report. World Health Organization; 2022. Licence: cc BY-NC-sa 3.0 IGO. URL: https://iris.who.int/handle/10665/363752
Published
2024-11-24
Section
Articles
Copyright (c) 2024 Eka Fitriana, James P. Simanjuntak, Herry Hermansyah, Karneli Karneli
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
